|POZEN Announces Election of Dr. Martin Nicklasson to the Board of Directors|
CHAPEL HILL, N.C., Jun 16, 2011 (BUSINESS WIRE) --
POZEN Inc. (NASDAQ: POZN), a pharmaceutical company committed to transforming medicine that transforms lives, today announced the election of Martin Nicklasson, Ph.D., to its Board of Directors at the Annual Meeting of Shareholders held on June 9, 2011. Dr. Nicklasson has been a senior leader in both large and small pharmaceutical organizations, and has held leadership roles in commercial operations and clinical development. Dr. Nicklasson held various Executive Vice President positions at AstraZeneca Plc. from 1999 to 2007, including Chairman of the Board of Astra Tech AB, a subsidiary of AstraZeneca (2004 to 2007), Executive Vice President, Global Marketing & Business Development (2005 to 2007), Executive Vice President, Global Drug Development (2002 to 2005) and Executive Vice President, Global Gastrointestinal Franchise (1999 to 2002). From 2007 to 2010, Dr. Nicklasson was the President and Chief Executive Officer of Biovitrum AB and Swedish Orphan Biovitrum AB, a publicly listed specialty pharma company. Dr. Nicklasson is currently a Senior Partner at Nicklasson Life Science AB, an independent consultancy and advisory company to the pharmaceutical and biotechnology sector. Dr. Nicklasson serves on the Board of the Stockholm Chamber of Commerce and the Board of the Heart and Lung Foundation of Sweden.
"We are pleased to welcome Dr. Nicklasson to the POZEN Board of Directors," said Dr. John R. Plachetka, POZEN's Chairman, President and Chief Executive Officer. "His years of pharmaceutical and life science experience will serve us well as we embark upon our new strategy."
POZEN Inc. is a progressive pharmaceutical company that is transforming how the healthcare industry addresses unmet medical needs. By utilizing a unique in-source model and focusing on integrated therapies, POZEN has successfully developed and obtained FDA approval of two self-invented products in two years - something almost no other small pharmaceutical company has done. Funded by these two milestone/royalty streams, POZEN is now creating a portfolio of cost-effective, evidence based integrated aspirin therapies designed to enable the full power of aspirin by reducing its GI damage. The lead candidate, PA32540, is being investigated for the secondary prevention of cardiovascular disease in patients at risk for aspirin-induced ulcers and has entered Phase 3 clinical trials. POZEN is retaining commercial control of the pipeline assets and will develop a 21st century sales and marketing organization using a new sales force model and digital communications. The Company's common stock is traded on The NASDAQ Stock Market under the symbol "POZN". For more detailed company information, including copies of this and other press releases, please visit: www.pozen.com.
SOURCE: POZEN Inc.